Shots:
- Astex has entered into an exclusive, worldwide research collaboration & license agreement with Genentech to identify small molecules with selective inhibitory activity for the treatment for breast cancer
- Astex will license compounds from its breast cancer discovery program to Genentech and jointly optimize lead compounds through preclinical candidate selection, after which Genentech will lead global development & commercialization
- Astex will receive $25M upfront & is eligible for over $490M in preclinical, clinical, regulatory, & sales milestones, plus tiered royalties on net sales of medicines arising from the collaboration
Ref: Globenewswire | Image: Genentech & Astex | Press Release
Related News: Genentech Reports the US FDA’s sBLA Acceptance of Lunsumio VELO + Polivy for R/R Large B-Cell Lymphoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
